Eupraxia Pharmaceuticals announces data from RESOLVE trial in EoE

Eupraxia Pharmaceuticals (EPRX) announced additional clinical data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis, including the first clinical data measured 52 weeks after patients were treated with EP-104GI. Patients treated with 4mg per injection of EP-104GI had meaningful levels of clinical remission as measured by Straumann Dysphagia Index at Week 12, Week 24, Week 36 and Week 52. Patients treated with 4mg per injection of EP-104GI demonstrated mean improvements in EoEHSS of 47% in grade and 44% in stage at week 36, continuing the trend of durable improvements in tissue health. Across dose groups, there is a significant correlation between pharmacokinetics and changes in tissue health. Plasma levels of fluticasone in patients treated with 4mg per injection of EP-104GI remained level and predictable out to 52 weeks. This is well below the levels typically observed with daily asthma inhalers which is shown as the red line on the graph. There have been no SAEs or incidence of either oral or gastrointestinal candidiasis reported to date.